Cargando…

Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007–2010

Monitoring the use of antibiotics is relevant due to the public health impact of microbial resistance, adverse effects, and costs. We present data on the consumption of macrolides, lincosamides, streptogramins and amoxicillin/clavulanate (AMC) between 2007 and 2010 in the in-and outpatient healthcar...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrer, Pili, Sabaté, Mònica, Ballarín, Elena, Fortuny, Joan, Rottenkolber, Marietta, Schmiedl, Sven, Laporte, Joan-Ramon, Ibáñez, Luisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628133/
https://www.ncbi.nlm.nih.gov/pubmed/26543747
http://dx.doi.org/10.1186/s40064-015-1398-4
_version_ 1782398388800585728
author Ferrer, Pili
Sabaté, Mònica
Ballarín, Elena
Fortuny, Joan
Rottenkolber, Marietta
Schmiedl, Sven
Laporte, Joan-Ramon
Ibáñez, Luisa
author_facet Ferrer, Pili
Sabaté, Mònica
Ballarín, Elena
Fortuny, Joan
Rottenkolber, Marietta
Schmiedl, Sven
Laporte, Joan-Ramon
Ibáñez, Luisa
author_sort Ferrer, Pili
collection PubMed
description Monitoring the use of antibiotics is relevant due to the public health impact of microbial resistance, adverse effects, and costs. We present data on the consumption of macrolides, lincosamides, streptogramins and amoxicillin/clavulanate (AMC) between 2007 and 2010 in the in-and outpatient healthcare setting in 10 European countries provided by IMS Health. Antibiotics were classified according to the anatomical therapeutic chemical classification and consumption was expressed in defined daily doses/1000 inhabitants/day (DIDs). We analysed the number of prescriptions by diagnostic codes between 2008 and 2010, based on the International Classification of Diseases, 10th revision (ICD-10). These ICD-10 codes were grouped into four main categories: respiratory infections, genitourinary infections, other infections and other diagnoses. In 2010, the consumption of macrolides and lincosamides ranged from 0.45 DIDs (Sweden) to 5.46 DIDs (Italy), and from 0.04 DIDs (Denmark) to 1.00 DID (Germany), respectively. Streptogramins were available in France, Germany, Italy, Norway, Spain and United Kingdom with a consumption of <0.001 DID exclusively in the hospital setting. The consumption of AMC ranged from <0.001 DIDs (Norway) to 11.67 DIDs (Spain). During the study period, the consumption of macrolides decreased, the consumption of AMC increased in most of European countries, and lincosamides varied very slightly. Macrolides and AMC were mainly prescribed for respiratory infections in all countries but United Kingdom, where most of the prescriptions were assigned to diagnostic codes not clearly related with an infection. Lincosamides were prescribed for the respiratory infections and other infections groups. There was a wide inter-country variability in the percentage of the prescriptions assigned to each of the diagnostic categories. The inter-country differences in the consumption of these antibiotics and their prescription by diagnostic categories point to an inappropriate use of antibiotics. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40064-015-1398-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4628133
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-46281332015-11-05 Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007–2010 Ferrer, Pili Sabaté, Mònica Ballarín, Elena Fortuny, Joan Rottenkolber, Marietta Schmiedl, Sven Laporte, Joan-Ramon Ibáñez, Luisa Springerplus Research Monitoring the use of antibiotics is relevant due to the public health impact of microbial resistance, adverse effects, and costs. We present data on the consumption of macrolides, lincosamides, streptogramins and amoxicillin/clavulanate (AMC) between 2007 and 2010 in the in-and outpatient healthcare setting in 10 European countries provided by IMS Health. Antibiotics were classified according to the anatomical therapeutic chemical classification and consumption was expressed in defined daily doses/1000 inhabitants/day (DIDs). We analysed the number of prescriptions by diagnostic codes between 2008 and 2010, based on the International Classification of Diseases, 10th revision (ICD-10). These ICD-10 codes were grouped into four main categories: respiratory infections, genitourinary infections, other infections and other diagnoses. In 2010, the consumption of macrolides and lincosamides ranged from 0.45 DIDs (Sweden) to 5.46 DIDs (Italy), and from 0.04 DIDs (Denmark) to 1.00 DID (Germany), respectively. Streptogramins were available in France, Germany, Italy, Norway, Spain and United Kingdom with a consumption of <0.001 DID exclusively in the hospital setting. The consumption of AMC ranged from <0.001 DIDs (Norway) to 11.67 DIDs (Spain). During the study period, the consumption of macrolides decreased, the consumption of AMC increased in most of European countries, and lincosamides varied very slightly. Macrolides and AMC were mainly prescribed for respiratory infections in all countries but United Kingdom, where most of the prescriptions were assigned to diagnostic codes not clearly related with an infection. Lincosamides were prescribed for the respiratory infections and other infections groups. There was a wide inter-country variability in the percentage of the prescriptions assigned to each of the diagnostic categories. The inter-country differences in the consumption of these antibiotics and their prescription by diagnostic categories point to an inappropriate use of antibiotics. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40064-015-1398-4) contains supplementary material, which is available to authorized users. Springer International Publishing 2015-10-15 /pmc/articles/PMC4628133/ /pubmed/26543747 http://dx.doi.org/10.1186/s40064-015-1398-4 Text en © Ferrer et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research
Ferrer, Pili
Sabaté, Mònica
Ballarín, Elena
Fortuny, Joan
Rottenkolber, Marietta
Schmiedl, Sven
Laporte, Joan-Ramon
Ibáñez, Luisa
Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007–2010
title Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007–2010
title_full Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007–2010
title_fullStr Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007–2010
title_full_unstemmed Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007–2010
title_short Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007–2010
title_sort sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 european countries, 2007–2010
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628133/
https://www.ncbi.nlm.nih.gov/pubmed/26543747
http://dx.doi.org/10.1186/s40064-015-1398-4
work_keys_str_mv AT ferrerpili salesofmacrolideslincosamidesstreptograminsandamoxicillinclavulanateintheinandoutpatientsettingin10europeancountries20072010
AT sabatemonica salesofmacrolideslincosamidesstreptograminsandamoxicillinclavulanateintheinandoutpatientsettingin10europeancountries20072010
AT ballarinelena salesofmacrolideslincosamidesstreptograminsandamoxicillinclavulanateintheinandoutpatientsettingin10europeancountries20072010
AT fortunyjoan salesofmacrolideslincosamidesstreptograminsandamoxicillinclavulanateintheinandoutpatientsettingin10europeancountries20072010
AT rottenkolbermarietta salesofmacrolideslincosamidesstreptograminsandamoxicillinclavulanateintheinandoutpatientsettingin10europeancountries20072010
AT schmiedlsven salesofmacrolideslincosamidesstreptograminsandamoxicillinclavulanateintheinandoutpatientsettingin10europeancountries20072010
AT laportejoanramon salesofmacrolideslincosamidesstreptograminsandamoxicillinclavulanateintheinandoutpatientsettingin10europeancountries20072010
AT ibanezluisa salesofmacrolideslincosamidesstreptograminsandamoxicillinclavulanateintheinandoutpatientsettingin10europeancountries20072010